LiquidArray® technology for TB / Mycobacteria diagnostics and beyond

 

Tuberculosis and nontuberculous mycobacteria are an alarming and ongoing global issue which requires fast and innovative diagnostics in order to fight the further spread of the diseases. Dr. Sandra Burrack-Lange will present the innovative LiquidArray^® technology from Bruker-Hain. Assays based on this technology generate a unique level of information and therefore sequencing-like depth of results. FluoroType^® MTB 2.0 is a sensitive semi-quantitative molecular genetic assay for the detection of tuberculosis complex from direct and cultured samples. With the WHO-recommended FluoroType^® MTBDR 2.0 a true MDR-TB testing from patient samples is possible: the assay identifies resistances to rifampicin and isoniazid as well as silent mutations within the rpoB gene. The respective mutations are shown in the result evaluation - so more than 50 mutations within the rpoB, inhA and katG genes are identified leading to up to 522 resistance patterns. We will present the complete workflow, from DNA isolation up to convenient result interpretation with the unique FluoroSoftware^®. Furthermore, upcoming developments with LiquidArray^® technology in the Mycobacteria field and beyond will be elaborated, as well as more syndromic panel PCR-based assays for other healthcare challenges. 

 

Learning Objectives